Analyzing XTL Biopharmaceuticals (NASDAQ:XTLB) and Cellectis (NASDAQ:CLLS)

XTL Biopharmaceuticals (NASDAQ:XTLB) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Valuation & Earnings

This table compares XTL Biopharmaceuticals and Cellectis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450,000.00	10.03	-$6.97 million	($0.64)	-2.97
Cellectis	$79.59 million	1.27	-$67.59 million	($0.65)	-1.56

XTL Biopharmaceuticals has higher earnings, but lower revenue than Cellectis. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for XTL Biopharmaceuticals and Cellectis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
Cellectis	2	2	2	1	2.29

Cellectis has a consensus target price of $5.46, indicating a potential upside of 440.06%. Given Cellectis’ stronger consensus rating and higher possible upside, analysts clearly believe Cellectis is more favorable than XTL Biopharmaceuticals.

Risk and Volatility

XTL Biopharmaceuticals has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500.

Profitability

This table compares XTL Biopharmaceuticals and Cellectis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Cellectis	-102.34%	-94.19%	-21.34%

Institutional and Insider Ownership

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cellectis beats XTL Biopharmaceuticals on 8 of the 15 factors compared between the two stocks.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.